If you are researching weight loss medication in 2026, the landscape is overwhelming: GLP-1 agonists, dual agonists, older appetite suppressants, combination drugs, and a pipeline of next-generation compounds. This guide ranks every FDA-approved weight loss medication by clinical efficacy, safety profile, cost, and real-world accessibility — so you can make an informed decision with your clinician.
The Definitive Ranking
| Rank | Medication | Avg Weight Loss | Brand Cost/mo | Compounded Cost | Key Advantage |
|---|---|---|---|---|---|
| 🥇 1 | Tirzepatide (Zepbound) | 22.5% | $1,060 | $349 | Most effective ever tested |
| 🥇 2 | Semaglutide (Wegovy) | 14.9% | $1,350 | $199 | Most studied, CV proven |
| 🥈 3 | Liraglutide (Saxenda) | 8% | $1,350 | Limited | Daily injection, older gen |
| 🥈 4 | Contrave (naltrexone/bupropion) | 5–6% | $300 | Generic available | Oral, targets cravings |
| 🥉 5 | Phentermine | 3–5% | $30–$75 | N/A (generic) | Cheap, short-term only |
| 🥉 6 | Topiramate/phentermine (Qsymia) | 7–9% | $200 | N/A | Oral, decent efficacy |
| 🥉 7 | Orlistat (Alli/Xenical) | 3% | $60 | OTC | No prescription needed |
Tier 1: GLP-1 / GIP Agonists (The Clear Winners)
Tirzepatide (Zepbound/Mounjaro)
The most effective weight loss medication ever tested. Dual GLP-1/GIP receptor agonist. SURMOUNT-1 showed 22.5% weight loss at 15mg. Superior insulin sensitivity improvement. Available as compounded tirzepatide for $349/month. For full pricing, see our tirzepatide cost guide. Side effects are manageable — see our tirzepatide side effects guide.
Semaglutide (Wegovy/Ozempic)
The most studied weight loss medication with the strongest outcomes data. The SELECT trial proved a 20% reduction in cardiovascular events. The FLOW trial proved kidney protection. Available as compounded semaglutide for $199/month. For help choosing between these two, see our decision guide.
Liraglutide (Saxenda)
The first-generation GLP-1 weight loss drug. Requires daily injection (vs. weekly for semaglutide). Produces 8% weight loss — roughly half of semaglutide. Still costs $1,350/month. There is almost no clinical scenario where liraglutide is preferred over semaglutide in 2026. For a full comparison, see our liraglutide vs. semaglutide analysis.
The #1 and #2 Ranked Medications. Both Available. From $199/mo.
TelehealthFX offers both compounded semaglutide ($199/mo) and tirzepatide ($349/mo). Your clinician recommends the right one for your profile.
Start Your EvaluationTier 2: Older Medications (Limited Utility)
Contrave (Naltrexone/Bupropion)
A combination pill targeting the brain's reward system. Average weight loss is 5–6% — one-third of semaglutide's. Best for patients who also have depression or addiction issues, as bupropion is an antidepressant and naltrexone blocks opioid receptors. Not a GLP-1 — does not improve cardiovascular or metabolic markers. For patients with emotional eating patterns, GLP-1 is typically more effective.
Phentermine
An amphetamine-class appetite suppressant approved since 1959. Very cheap ($30–$75/month). Produces modest weight loss (3–5%). But it has significant limitations: FDA-approved for only 12 weeks of use, carries cardiovascular risks (increased heart rate, elevated blood pressure), and does not address the hormonal drivers of weight regain. After stopping, weight returns rapidly. Not recommended for patients with cardiovascular risk — the opposite of semaglutide's cardioprotective effect.
Orlistat (Alli/Xenical)
A lipase inhibitor that blocks fat absorption in the gut. Average weight loss is only 3%. Available over-the-counter (Alli) or by prescription (Xenical). Side effects are severe and socially devastating: oily stools, fecal incontinence, fat-soluble vitamin malabsorption. In 2026, there is no clinical rationale for choosing orlistat over GLP-1 therapy.
The Pipeline: Next-Gen Drugs Coming 2027–2029
The weight loss medication landscape is evolving rapidly. For a deep dive into upcoming drugs, see our next-gen GLP-1 pipeline guide. Key compounds to watch:
- Survodutide (Boehringer Ingelheim): Glucagon/GLP-1 dual agonist. Phase 3 results show ~19% weight loss. May also treat fatty liver disease.
- Orforglipron (Eli Lilly): Non-peptide oral GLP-1. Higher bioavailability than Rybelsus. Could be the first practical oral GLP-1 for weight loss.
- Amycretin (Novo Nordisk): GLP-1/amylin co-agonist. Early Phase 2 data shows ~25% weight loss — potentially exceeding tirzepatide.
- Retatrutide (Eli Lilly): Triple agonist (GLP-1/GIP/glucagon). Phase 2 showed 24% weight loss.
Frequently Asked Questions
What is the most effective weight loss medication in 2026?
Tirzepatide (Zepbound) produces the highest average weight loss at 22.5%. Semaglutide (Wegovy) is second at 14.9% but has stronger cardiovascular outcome data. Both are available through compounding. See our head-to-head comparison.
Can I combine weight loss medications?
Combining GLP-1 agonists with other GLP-1 agonists is not recommended. However, metformin is sometimes used alongside GLP-1 for patients with significant insulin resistance. Always discuss combination therapy with your clinician.
What is the cheapest option?
Among effective medications: compounded semaglutide at $199/month offers the best value per pound lost. Phentermine is cheaper ($30–$75) but produces 1/3 the weight loss and cannot be used long-term. See our cost-without-insurance guide.
Access the #1 and #2 Ranked Medications. Today.
Semaglutide from $199/mo. Tirzepatide from $349/mo. Clinician-guided. HSA/FSA accepted.
Get StartedReferences
- Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 387(3), 205–216.
- Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 384(11), 989–1002.
- Apovian, C. M., et al. (2015). Pharmacological management of obesity (AHA/ACC/TOS). JCEM, 100(2), 342–362.
- Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity (SELECT). NEJM, 389(24), 2221–2232.